Table 4.
Comparative analysis of the clinicopathological data between the anti-PLA2R antibody-positive and negative groups.
| Parameters | anti-PLA2R antibody-negative(n = 155) | anti-PLA2R antibody-positive(n = 125) | p |
|---|---|---|---|
| Age(years) | 47.6 ± 14.9 | 48.4 ± 13.7 | .616 |
| Gender(male/%) | 95(61.3%) | 72(57.6%) | .532 |
| Hematuria, n (%) | 36(23.2%) | 25(20.0%) | .516 |
| Hypertension, n (%) | 72(46.5%) | 52(41.6%) | .417 |
| Serum albumin (g/L) | 30.2 ± 6.5 | 26.1 ± 4.3 | <.001 |
| Serum creatinine(μmol/L) | 80.2 ± 29.1 | 78.3 ± 30.7 | .752 |
| eGFR (ml/min/1.73m2) | 96.8 ± 25.0 | 94.8 ± 23.9 | .503 |
| Proteinuria (g/24h) | 5.7 ± 3.6 | 6.7 ± 3.3 | .018 |
| Uric acid(umol/L) | 385.9 ± 96.2 | 375.6 ± 98.6 | .419 |
| Triglycerides (mmol/L) | 2.6 ± 1.6 | 2.8 ± 2.0 | .329 |
| Cholesterol (mmol/L) | 6.8 ± 2.0 | 8.1 ± 2.5 | <.001 |
| Serum-IgG (mg/dl) | 751.9 ± 321.7 | 614.9 ± 230.1 | <.001 |
| Serum-IgM (mg/dl) | 109.8 ± 54.2 | 111.4 ± 52.5 | .791 |
| Serum-IgA (mg/dl) | 225.7 ± 104.6 | 225.8 ± 110.8 | .995 |
| Serum-C3 (mg/dl) | 102.1 ± 22.9 | 99.8 ± 22.1 | .387 |
| Serum-C4 (mg/dl) | 24.6 ± 7.2 | 25.5 ± 7.0 | .270 |
| IgG deposit, n (%) | 152(98.1%) | 124(99.2%) | .772 |
| IgM deposit, n (%) | 115(74.2%) | 98(78.4%) | .412 |
| IgA deposit, n (%) | 141(91.1%) | 115(92.0%) | .759 |
| C3 deposit, n (%) | 148(95.5%) | 122(97.6%) | .343 |
| C1q deposit, n (%) | 142(91.6%) | 114(91.2%) | .902 |
| IgG1 deposit, n (%) | 153(98.7%) | 122(97.6%) | .487 |
| IgG2 deposit, n (%) | 132(85.2%) | 97(77.6%) | .103 |
| IgG3 deposit, n (%) | 29(18.7%) | 21(16.8%) | .678 |
| IgG4 deposit, n (%) | 142(91.6%) | 123(98.4%) | .012 |
Note: The estimated glomerular filtration rate (eGFR) was calculated using the CKD-EPI formula [16].